0
Boehringer Ingelheim Animal Health, a market-leading manufacturer of swine vaccines, has decided to remain focused on freshly mixed Porcine Circovirus type 2 (PCV2)/Mycoplasma hyopneumoniae (M.hyo) vaccines and not follow the development of a PCV2/M.hyo ready-to-use (RTU)*1 vaccine combination. As a consequence, the company has discontinued its PCV2/M.hyo RTU research program.
Although initial data was promising, it became evident over time that in this case, the RTU design does not meet the high standards of efficacy and safety for which Boehringer Ingelheim’s FLEXcombo® platform*2 is known. In essence, Boehringer Ingelheim´s PCV2/M.hyo research program revealed that the highest protection against both pathogens was observed for its vaccines when freshly mixed and applied in accordance with manufacturer recommendations.
The FLEXcombo® platform of mixable vaccines protects pigs against PCV2 and M.hyo with a single dose. In 2013, Boehringer Ingelheim introduced the MycoFLEX® headspace bottle, a simple and practical way to mix the two pig vaccines Ingelvac CircoFLEX® and Ingelvac MycoFLEX® for their simultaneous application. The same trusted concept is used for 3FLEX®, the mix of Ingelvac CircoFLEX®, Ingelvac MycoFLEX® and Ingelvac PRRS MLV® which is presently licensed in North America and several Asian countries.
Ingelvac CircoFLEX® is established globally as market leader for PCV2-vaccination*3 while Ingelvac MycoFLEX® is the market leader in a number of key swine markets*4. Boehringer Ingelheim is dedicated to continue its research efforts on these core antigens.
*1 In a ready-to-use (RTU) design, PCV2 (Porcine Circovirus type 2) and M.hyo (Mycoplasma hyopneumoniae) vaccines are pre-manufactured and stored in one bottle for later use.
*2 The FLEXcombo vaccine platform allows an easy mixing of Ingelvac CircoFLEX® and Ingelvac MycoFLEX® immediately before vaccination.
*3 Local and international market research data 2010, 2011, 2012, 2013, Q1-Q2 2014.
*4 Ingelvac MycoFLEX® market leadership includes markets like USA, Germany, The Netherlands, Italy, Poland, South Korea, Thailand and Taiwan and is based on 2013 local and international market research data (data on file).
September 1, 2014 - Boehringer
